Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis
When used in addition to standard of care, MSDA demonstrates clinical utility for real-world decision-making in MS management, based on objective changes in treatment plan and clinician<b>-</b>reported impact, which increases with longitudinal use.
Authors
- James L. Eubanks
- Martin Belkin
- Patricia Izbicki (ORCID: https://orcid.org/0000-0002-3269-2668)
- Megan Weigel (ORCID: https://orcid.org/0000-0001-8945-4954)
- Jacqueline Nicholas (ORCID: https://orcid.org/0000-0002-6328-1941)
- Michael Sy (ORCID: https://orcid.org/0000-0003-4826-0066)
- William Kilgo
- Yasir Jassam
- Jon M. Burnham (ORCID: https://orcid.org/0000-0002-9438-1072)
- Shannon R. McCurdy (ORCID: https://orcid.org/0000-0002-2813-6781)
- Ferhan Qureshi (ORCID: https://orcid.org/0000-0002-5158-0485)
- Sarah L. Eagleman (ORCID: https://orcid.org/0000-0003-1584-7135)
- Mitzi Williams (ORCID: https://orcid.org/0000-0001-6979-1101)
- Ati Ghoreyshi
- Elisa Sheng
- Angela J. Sanchez
- Annette Okai (ORCID: https://orcid.org/0009-0005-7775-3013)
- Taylor Gonyou
- Matt Burril
Institutions
- OhioHealth (US)
- Neurosciences Institute (US)
- University of California, Irvine (US)
- Multiple Sclerosis Research Institute (US)
- Michigan Institute for Neurological Disorders (US)
- Texas Neurology (US)
- Baptist Medical Center Beaches (US)
- University of South Alabama (US)
Publication Details
- Journal
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1177/20552173251331030
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47